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Abstract
Nucleoside analogs used in antiretroviral treatment have been associated with mitochondrial toxicity. The polymerase-c
hypothesis states that this toxicity stems from the analogs’ inhibition of the mitochondrial DNA polymerase (polymerase-c)
leading to mitochondrial DNA (mtDNA) depletion. We have constructed a computational model of the interaction of
polymerase-c with activated nucleoside and nucleotide analog drugs, based on experimentally measured reaction rates and
base excision rates, together with the mtDNA genome size, the human mtDNA sequence, and mitochondrial dNTP
concentrations. The model predicts an approximately 1000-fold difference in the activated drug concentration required for
a 50% probability of mtDNA strand termination between the activated di-deoxy analogs d4T, ddC, and ddI (activated to
ddA) and the activated forms of the analogs 3TC, TDF, AZT, FTC, and ABC. These predictions are supported by experimental
and clinical data showing significantly greater mtDNA depletion in cell culture and patient samples caused by the di-deoxy
analog drugs. For zidovudine (AZT) we calculated a very low mtDNA replication termination probability, in contrast to its
reported mitochondrial toxicity in vitro and clinically. Therefore AZT mitochondrial toxicity is likely due to a mechanism that
does not involve strand termination of mtDNA replication.
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Introduction
Current guidelines for highly active anti-retroviral treatment
(HAART) regimens of HIV-positive patients recommend two
drugs of the nucleoside reverse transcriptase inhibitor (NRTI) class
(Table 1) [1]. This class currently consists of: stavudine (d4T),
lamivudine (3TC), zidovudine (AZT), zalcitabine (ddC), didano-
sine (ddI), abacavir (ABC), emtricitabine (FTC) and tenofovir
(TDF, a nucleotide analog). Though zalcitabine (ddC) at the time
of this writing is still technically approved for treatment its
distribution in the United States was discontinued by Roche in
2006. In their activated tri-phosphorylated forms, each NRTI acts
as a nucleotide analog interacting with the HIV viral reverse
transcriptase as an alternative substrate to the natural nucleotides
[2,3]. Each of these analogs lacks the 39 OH group necessary for
incorporation of the next nucleotide thereby terminating viral
DNA strand elongation. Although NRTIs are effective drugs and
have helped usher HIV into the category of a controllable chronic
disease, they are also often toxic, inducing side effects such as lactic
acidosis, neuropathy, nausea, lypodistrophy, and myopathy in
patients. Intolerance of such side effects is a common reason for
treatment discontinuation [4]. Any decrease in patient compliance
to the treatment regimen is a serious concern that can lead to an
increase in viral resistance and ultimately to treatment failure. The
first step in ameliorating these side effects and preventing them in
future antiviral treatments is to understand the mechanisms
behind the mitochondrial toxicity of the NRTIs that are in use
today. As we discuss below, many mechanisms of the mitochon-
drial toxicity have been proposed. In this paper we specifically
consider the plausibility of the currently most widely accepted
hypothesis for the toxicity mechanism for this class of drugs;
interference of mitochondrial DNA replication by the activated
drug.
The Polymerase-c Hypothesis
Polymerase-c (pol–c) is the only polymerase responsible for
mitochondrial DNA replication. While pol-c is not believed to
directly regulate mtDNA levels, pathogenic mutations in the gene
POLG do affect the stability of mtDNA and cause mtDNA
depletion [5]. Polymorphisms found in the POLG gene in the
human population may cause a natural variability in the activity of
this complex enzyme and may conceivably play a role in patient
variability in NRTI drug toxicities.
In a study conducted by Martin et al. [6] the approved NRTIs
were shown to inhibit various host DNA polymerases. After the
HIV Reverse Transcriptase, the highest affinity of the NRTIs was
for polymerase-c. This, along with the fact that many of the NRTI
side-effects resemble symptoms of mitochondrial genetic disorders,
implicated interaction with polymerase-c and subsequent deple-
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the polymerase-c hypothesis [7]. Indeed, experiments have
demonstrated decreased mtDNA amounts in various tissue types
of NRTI-treated HIV positive patients [8–11]. In addition,
mtDNA depletion was observed in parallel with cell death,
mitochondrial morphological changes, and increased lactate
production in liver, heart, neuron, skeletal muscle, adipose, and
blood cell cultures after incubation with different NRTIs [12–20].
The possible polymerase-c dependent toxicity mechanisms that
comprise the polymerase-c hypothesis are (i) direct inhibition of
polymerase-c by NRTI-triphosphate without incorporation into
the mtDNA, (ii) chain termination of mtDNA replication following
incorporation of the NRTI triphosphate, and (iii) incorporation of
the analog triphosphate into mtDNA without chain-termination
allowing the NRTI to continue as a point mutation in mtDNA
[21].
However, there also exists a substantial body of data that are not
consistent with toxicity mechanisms resulting in depletion of
mtDNA. Martin et al. [6] showed no association between
inhibition of polymerase-c by NRTIs and mtDNA depletion.
Mitochondrial dysfunction has been observed in vitro in mouse
muscle, white adipose, brain, liver, and heart tissue [22],
hepatoma cell lines [20] as well as CD4 cells [19] after incubation
with NRTIs although no significant decrease in mtDNA amount
was observed. Particularly, incubation of liver and skeletal muscle
cells with ddC, ddI, d4T, and AZT show a higher rate of lactate
production in the presence of AZT, but the least amount of
mtDNA depletion [15,18]. In clinical settings mtDNA depletion
has been seen in parallel with normal cytochrome c oxidase
activity, a sign of correct mitochondrial function [23], and was not
associated with lipoatrophy [24] (although that study measured
mtDNA depletion in blood samples, not fat cells). Taken together,
these findings indicate a weak relationship between mtDNA copy
number and nucleoside analog toxicity. This warrants a deeper
look at the data concerning the interaction of different NRTIs with
polymerase-c. To this end, we have simulated the DNA
replication process of mitochondria. Using enzyme kinetics data
gathered from Johnson et al. [25], Feng et al. [26], and Hanes et
al. [27,28] we have carried out a series of simulations of mtDNA
replication in the presence of various nucleoside analogs that
interact with polymerase-c (Table 2). These simulations bridge the
gap between the basic enzyme kinetics data and the probability of
failure of the mtDNA replication process.
Methods
The Drugs Included in this Study
Thirteen analogs were used in the simulations (Table 1). These
included eight drugs of the NRTI class currently approved for
human treatment- stavudine (d4T), lamivudine (3TC(2)), zidovu-
dine (AZT), zalcitabine (ddC), didanosine (ddI) (whose active form
is dideoxyadenosine (ddA) triphosphate), abacavir (ABC), emtri-
citabine (FTC(2)) and tenofovir (TDF) [1], and one anti-herpes
drug, acyclovir (ACV). In addition we modeled the effects of the
natural enantiomers of FTC(+) and 3TC(+) that have been used to
explore a possible role of stereochemistry in the efficacy of strand
termination [29], and ddI in its non-activated form. Since this
Table 1. Nucleoside and nucleotide analogs used in this study.
Drug Abbreviation Natural Nucleoside Comment
Abacavir ABC dG The activated form is CBV-TP.
Acyclovir ACV dG Used in treatment against Herpes viruses including HSV1 and 2, chickenpox and herpes zoster.
Didanosine ddI dA Must be aminated to become ddA, which is activated form. The nonactivated form, however,
has also been shown to incorporate into mtDNA.
Dideoxyadenosine ddA dA The active form of ddI.
Emtricitabine FTC(2) dC The unnatural enantiomer that is approved for treatment of HIV.
Emtricitabine FTC(+) dC The natural enantiomer that is more toxic and not approved for treatment.
Lamivudine 3TC(+) dC This natural enantiomer of 3TC is not used in treatment, but is used in studies that look at
effects of configuration on toxicity and efficacy.
Lamivudine 3TC(2) dC The unnatural enantiomer that is approved for treatment of HIV.
Stavudine d4T T
Tenofovir PMPA, TDF dAMP A nucleotide analog.
Zalcitabine ddC dC Not currently recommended for clinical use.
Zidovudine AZT T
doi:10.1371/journal.pcbi.1000261.t001
Author Summary
While HIV/AIDS therapy is very successful at controlling
HIV infection, the therapy must continue for the remainder
of the patient’s life. Approximately one-fourth of these
patients suffer from serious drug toxicity problems. It is
generally believed that the toxicity of these drugs is
caused by damage to mitochondria, the ‘‘power plants’’ of
every cell. But we do not know exactly how this damage
occurs. The most common explanation is that these drugs
damage mitochondria in the same way that they control
the virus, by interfering with DNA replication. We tested
that idea by analyzing data for the interaction of several
AIDS drugs with the mitochondrial DNA polymerase, the
protein responsible for copying mitochondrial DNA. By
using a detailed simulation of the mitochondrial DNA
polymerase, we show that some of these drugs do interact
well enough with the mitochondrial DNA polymerase to
lead to toxic effects. However, many of these drugs,
including the commonly used drug AZT, had very little
toxic effect in this simulation although AZT often causes
toxicity in patients. This indicates that the toxicity of AZT
occurs through some other process and not through the
direct interruption of mitochondrial DNA replication.
mtDNA Strand Termination by NRTIs
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an anti-hepatitis B drug that tragically resulted in the deaths of five
patients in phase 2 trials and whose toxicity is believed to be due to
errors in mtDNA replication [30,31], though not necessarily
through strand termination [25,31].
Computational Model
Our computational model of the mitochondrial DNA replica-
tion process is based on the Stochastic Simulation Algorithm
[32,33], a well-known Monte Carlo simulation method for
chemical reactions. The model is based on four reactions; DNA
polymerase activity, exonuclease activity, disassociation of the
polymerase from the DNA, and reassociation of the polymerase
with the DNA molecule (Figure 1). In the DNA polymerase
reaction pol-c adds one nucleotide to the new DNA strand. This
nucleotide may be the correct or incorrect (point mutation) base
indicated by the template strand. In this model this includes the
incorporation of nucleoside analog triphosphates. In the exonu-
clease reaction pol-c removes one nucleotide from the new DNA
strand. This includes the removal of nucleoside analogs from the
DNA strand. The exonuclease reaction is an error correction
mechanism, as the rate for removal of incorrectly incorporated
nucleotides is typically faster than that of correctly incorporated
nucleotides. In the disassociation reaction the polymerase
separates from the DNA molecule. In the reassociation reaction
the polymerase re-attaches to the DNA molecule after disassoci-
ation. At each position on the replicating mtDNA strand, pol-c
will randomly undergo one of the first three reactions (polymerase,
exonuclease, or dissociation). Which reaction pol-c undergoes is
determined by the probability of each reaction, calculated using
the reactions rates and Michaelis-Menten kinetics.
For the two scenarios of a correctly inserted and incorrectly
inserted previous nucleotide we have separate sets of kinetic
parameters for each of the pol–c reactions [34–36]. These studies
have reported an increase in exonuclease and disassociation rates,
but a decrease in incorporation rates by pol-c following an
incorrect incorporation. This is included in the simulation model
by using two sets of enzyme kinetics parameters, one set for
reactions following a correct incorporation and another set for
reactions following an incorrect incorporation. Kinetic parameters
for the natural nucleotide (dNTP) interaction with pol-c are
available in Text S1. As data regarding the reassociation reaction
rate are not available our model assumes that after a disassociation
event occurs the reassociation reaction follows, except in the
special case discussed immediately below. Since the rate for the
reassociation reaction is not available, the time required for that
reaction is not calculated in this model. This approximation is not
important to our results reported here which focus on strand
termination probabilities.
Upon incorporation of an analog into the new DNA strand the
next polymerase reaction is blocked. The exonuclease reaction can
still occur, removing the analog molecule. However, if a
disassociation reaction occurs before the analog can be removed,
we assume that reassociation of the DNA polymerase is also
blocked and the mtDNA replication event is disrupted resulting in
strand termination (Figure 1). There has been some speculation
Table 2. Enzyme kinetics parameter values used for
polymerase-c interaction with each activated analog, in order
of decreasing kcat/Km.
NRTI Km (mM) kcat (sec
21)k cat/Km (mMs e c )
21 Vexo (sec
21)
ddC 0.041 0.660 16.1 0.00002
ddA 0.022 0.310 14.1 0.0005
d4T 0.045 0.24 5.33 0.0004
FTC(+) 0.79 0.84 1.1 0.0048
3TC(+) 1.5 0.35 0.23 0.02
Acyclovir 6 1.03 0.17 0.0021
ddI 6.3 0.15 0.024 0.0007
3TC(2) 9.2 0.125 0.01 0.015
TDF 40.3 0.21 0.005 0.0007
AZT2001 187 0.2 0.001 0.0004
ABC 13 0.0018 0.0014 0.0016
FTC(2) 62.9 0.0086 0.00014 0.0048
AZT2007 280 0.001 0.0000036 Not reported
Enzyme kinetics data taken from references [25–28].
doi:10.1371/journal.pcbi.1000261.t002
Figure 1. Schematic diagrams of the polymerase-c reactions in
this model. (A) The four reactions possible following a correct
incorporation. DNA Polymerase: polymerase-c adds one nucleotide to
the new DNA strand. This nucleotide may be the correct or incorrect
(point mutation) base pair for template strand, or a nucleotide analog.
Exonuclease: polymerase-c removes one nucleotide (correct or
incorrect match) from the new DNA strand. This is an error correction
mechanism. Disassociation: The DNA polymerase can separate from the
DNA molecule. Reassociation: The DNA polymerase re-attaches to the
DNA molecule after disassociation. (B) The possible reactions after
insertion of analog (Z to represent AZT in this example): exonuclease
activity or dissociation. Our model does not allow further polymeriza-
tion or reassociation once an analog is inserted and not removed by an
exonuclease reaction.
doi:10.1371/journal.pcbi.1000261.g001
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replicating mtDNA strand without causing strand termination. In
this model we take the conservative assumption that all NRTIs
that are inserted in the mtDNA strand and not subsequently
removed cause strand termination.
Parameters included in the model for incorporation of each
analog by pol- c were the concentration necessary for binding of
50% of available pol-c (Km), the rate of polymerization (kpol),, and
the rate of excision (Vexo) of each analog by pol-c. The parameters
kpol and Km were estimated from the maximum rate of
incorporation by pol-c (kcat) and the dissociation constant from
pol-c (Kd), respectively, obtained under pre-steady state conditions
[25–27]. A recent publication shows that pyrophosphate release
from AZT is uniquely slow during polymerization and that kinetics
measured during steady-state conditions give a more accurate kpol
estimation [27]. These measurements were carried out on AZT
due to the fact that under pre-steady state conditions a decrease in
incorporation rate was observed with increased AZT concentra-
tion indicating reversible binding. This pattern was not seen with
any of the other analogs studied (d4T, 3TC(2), AZT, ddC, ddI,
ddA, ABC, TDF, and 3TC(+)) and for this reason reanalysis of the
enzyme kinetics for those drugs was not performed in that
experiment. Given this continuing evolution in our understanding
of the AZT kinetics we carried out two simulations for AZT
insertion using the two available published sets of parameters
determined under steady-state conditions in the 2007 paper by
Hanes and Johnson [27] and pre-steady state conditions published
in the 2001 paper by Johnson et al. [25]. We distinguished the
results using these two parameter sets as AZT2001 and AZT2007.
These parameter values, as well as those for the other analogs, are
given in Table 2.
Triphosphorylated Mitochondrial Natural Nucleotide
(dNTP) Levels
The polymerization reaction rates are functions of the dNTP
concentrations. For this calculation we consider three sets of dNTP
concentrations, representing high, medium and low concentration
conditions. Mitochondrial dNTP levels were estimated following
the observations of Rampazzo et al and Ferraro et al [37,38]
(Table 3). The units of picomole of mitochondrial dNTP per mg of
mitochondria or picomoles per 10
6 cells were converted to mMb y
using an assumed mitochondrial volume of 0.2 femtoliters and
density measurements from Pollak and Munn [39]. It should be
noted that these density measurements considered mitochondria
as discrete entities not taking in to account any change in
mitochondrial size due to organelle fission and fusion processes.
We use these values only as estimates, in order to define the three
categories of dNTP concentrations given below.
High dNTP levels. As an estimate for the natural nucleotide
concentrations within mitochondria of actively dividing cells,
concentrations of natural nucleotides in mitochondrial pools from
a cycling cell culture of 3T3-L1TK1+ (a mouse fibroblast line)
were used. [38]. The units of dNTP measurement were converted
to mM units by estimating the volume of a 3T3-L1 cell from
images in Friis et al. [40].
Medium dNTP levels. As an estimate of the natural
nucleotide concentrations within mitochondria of resting or
slowly dividing cells values for rat liver cells were used [41].
Low dNTP levels. A third set of simulations were carried out
using natural nucleotide levels at 1/10th those estimated for the
liver cells. This is meant to represent the low dNTP concentrations
in postmitotic cells.
Simulation Sets
Vertebrate mitochondrial DNA has a highly asymmetric G
content. The low-G strand is labeled the light strand, with the
complement strand called the heavy strand. Sets of simulations
were carried out separately for the light strand sequence (NCBI, gi
17981852) and the heavy strand sequence. On each template three
separate simulation sets were carried out using the high, medium,
or low natural nucleotide concentrations described above and
varying the concentration of activated triphosphorylated analog.
Each simulation was repeated 1000 times. The number of
simulated mtDNA strand replications ending in a strand
termination event (caused by a nucleoside analog incorporation)
was recorded. The concentrations of the four dNTP pools and the
activated analog were held constant throughout each simulated
replication.
Results
The purpose of this study was to explore the plausibility of the
pol-c hypothesis by calculating the probability of insertion of the
nucleotide analog into the replicating mtDNA strand, leading to
strand termination. We constructed a model based on the
mitochondrial genome length and sequence, mitochondrial dNTP
concentrations, and the measured enzyme kinetics of pol-c. With
this model we simulated mitochondrial DNA replication in the
presence of different analogs determining the dose response curves
and the IC50 values of DNA termination for each drug. The
simulation results were compared to reports of mitochondrial
toxicity, and specifically to reports of mtDNA depletion.
Dose Response Curves and IC50 Values
By measuring the probability of strand termination in the
simulation as a function of the activated drug concentration, dose
response curves for each drug were calculated. Figure 2 shows the
dose response curves obtained for the strand termination
probability of each clinically approved analog as a function of
the analog mitochondrial concentrations. The concentration at
which these dose response curves passed 50% defined the IC50
values for each activated drug (Table 4). In our model, replication
was terminated once an analog was inserted and failed to be
removed by exonuclease activity. Based on these simulated IC50
values the list of analogs in the order of decreasing probability of
mtDNA strand termination on the light strand was:
ddC=ddA=d4T.FTC(+).3TC(+).ACV.ddI.3TC(2)=
TDF.=AZT2001..FTC(2).ABC=AZT2007 in which ‘‘..’’
indicates a 10 fold difference or more, ‘‘.’’ indicates a 2 to 10
fold difference and ‘‘=’’ indicates a less than 2 fold difference.
Note that ddA is the activated form of ddI. Of this list only
d4T, ddI, ddC, 3TC(2), TDF, AZT, ABC, ACV and FTC(2)
are approved for therapeutic use. The IC50 list showed that the
‘‘di-deoxy drugs’’, meaning ddC, d4T, and ddA, had the highest
Table 3. Mitochondrial dNTP concentrations and Km values.
dNTP Level dATP (mM) dCTP (mM) dGTP (mM) dTTP (mM)
High 22.5 28 19.5 26
Medium 1.675 1.644 0.47 0.76
Low 0.1675 0.1644 0.047 0.076
Km with
polymerase-c
a
0.8 0.9 0.8 0.6
aFrom reference [36].
doi:10.1371/journal.pcbi.1000261.t003
mtDNA Strand Termination by NRTIs
PLoS Computational Biology | www.ploscompbiol.org 4 January 2009 | Volume 5 | Issue 1 | e1000261probability of causing mtDNA strand termination during replica-
tion while FTC(2), ABC and AZT2007 showed the least. Of those
drugs approved for HIV treatment there was an observed difference
of more than 800 fold between the di-deoxy drugs (ddC, ddA, and
d4T) and other approved drugs (3TC, TDF, AZT, ABC, and
FTC(2)) in the activated drug concentration necessary for 50%
probability of mtDNA strand termination.
The only difference seen in the simulation of heavy strand
replication (Text S1) was that acyclovir had a slightly higher
probability of termination than 3TC(+) and ABC had approxi-
mately equal probability of termination as FTC(2). Since there
was little difference in the results for the two strands of the mtDNA
molecule, we concentrated on results from the light strand. For the
readers’ convenience in interpreting these IC50 values, reported
ranges of intracellular concentrations [42–48] for activated
nucleoside analog drugs measured in peripheral blood mononu-
clear cells in patients are given in Table 5. Where necessary, values
were converted to units of mM using the conversion of Kewn et al
[45]. However it should be kept in mind that these concentrations
are intracellular values, not the concentration values in the
mitochondria which may be different.
Abacavir, Emtricitabine, and Zidovudine2007
For most analogs, the simulated dose response curve increases to
100% probability of strand termination if the analog concentration
is raised high enough. AZT2007, ABC and FTC(2) behaved
differently from the other analogs in that they reached the point of
saturation below 100% probability of strand termination (Figure 2),
and in some cases the strand termination probability saturated
below 50%, meaning that no IC50 values could be defined in those
cases (the blank entries in Table 4). These three analogs interact so
poorly with pol-c that over the finite length of the mtDNA sequence
(approximately 16,600 base pairs) these analogs have too few
chances to incorporate into the growing mtDNA strand for the
probability of strand termination to approach 100%, even with very
large concentrations of the activated drug in the mitochondrion.
When the recently revised steady-state derived parameters for
kcat and Km for AZT [27] were used in the simulation, AZT2007
did not reach a 50% probability of strand termination in the
presence of normal to high dTTP levels, instead saturating at a
23% probability. This grouped AZT2007 with ABC as having the
least probability of causing termination of the replicating mtDNA.
Specificity Constant
A common measurement for the relative likelihood of strand
termination by each analog is the specificity constant [25]
determined by the ratio kcat/Km for the incorporation of an
analog by pol-c. This is a common measurement used for
predicting the discrimination of analogs by pol-c over the natural
nucleotide substrate [25–28]. The drawback in taking this
measurement of direct interaction with pol-c as a predictor for
the actual incorporation into the replicating mtDNA strand is that
the specificity constant does not consider exonuclease activity,
mitochondrial dNTP levels, nor strand length, all of which can
affect the probability that an analog will be incorporated. All of
these factors of the system are integrated into our computational
model and the resulting IC50 values. Previous studies [25–28]
provide a list of increasing specificity constants of: ddC.ddA.
d4T..ACV.3TC(2).TDF.AZT..ABC=FTC(2). The or-
der of this list agreed quite well with our list given above based on
simulated mtDNA strand termination. Thisagreement validates the
use of kcat/Km values as an appropriate proxy for the relative
probability ofincorporation oftheseNRTIsby pol-c. A quantitative
comparisonbetweenthespecificityconstantandourcalculated IC50
for strand termination is given in Figure 3.
Removal of Nucleoside Analogs from the mtDNA
The very low exonuclease reaction rate for each analog is the
primary reason why the specificity constant serves as a reasonable
prediction of mtDNA strand termination. The exonuclease
reaction rates used in this study were taken from Johnson et al.
[25]. Low excision rates for NRTIs have also been documented in
the case of ddC [49] and using yeast mtDNA polymerase with
ddC and AZT [50]. However, 3TC has a non-negligible measured
exonuclease rates (Table 2) [25]. Whenever an analog is inserted
into the DNA strand, our pol-c model assumed that only the
exonuclease and pol-c dissociation reactions can occur. Based on
this model, in Table 6 we give the predicted probability Pexo of the
analog removal
Figure 2. The dose-response curves for incorporation probability of analogs approved for treatment. Circles are the probability of
strand termination calculated from a set of 1000 simulations for each point and the curves are dose-response curves fit to the data points. There is a
large difference of incorporation probability between the di-deoxy drugs (ddC, ddI, and d4T) and other approved anti-retrovirals (3TC, TDF, AZT, ABC,
and FTC). The anti-herpes drug, acyclovir, falls in the middle of these two extremes, but shows little mitochondrial toxicity in clinical use possibly due
to the fact it is dependent upon viral proteins for activation. AZT2001 probabilities were determined using kinetic parameters from reference [25] and
AZT2007 probabilities were determined using newly reported kinetic parameters from reference [27].
doi:10.1371/journal.pcbi.1000261.g002
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where Vexo is the rate of exonuclease reaction for the analog and
Vdis is the rate of disassociation of the polymerase. To test these
predictions, we carried out a set of simulations with the analog
exonuclease reactions removed. The ratio of the IC50 value in the
full model to the IC50 value in the exonuclease deficient model was
in very good agreement with the 1-Pexo values (Table 6). As
predicted, only the two 3TC forms showed significant effects from
the removal of the analog exonuclease reaction. Even in these
cases the effect of the exonuclease reaction only shifted the IC50
value by a factor of 2 or less.
Effects of Multiple Nucleoside Analogs
The current therapy for HIV infections involves a combination
of nucleoside analog drugs, along with another class of drug such
as a protease inhibitor. It has been reported that combining
nucleoside analogs increases toxicity [51,52]. The pol-c model is a
series of reactions occurring as the DNA polymerase moves along
the template strand. At each position on the DNA strand different
nucleoside analogs would be able to be incorporated into the DNA
strand. For example, AZT triphosphate molecules would only
have a reasonable rate of incorporation opposite an A on the
template strand, while 3TC triphosphate molecules would only
have a reasonable rate of incorporation opposite a G on the
template. Considering this, it is unlikely that there could be a
combined effect of two analogs of different nucleosides on strand
termination through the pol-c interaction alone. To test this, we
modeled the effects of two analogs, AZT and 3TC, separately and
in combination (Figure 4). The combination of AZT and 3TC has
been shown to have enhanced toxicity [51,52], though neither of
these two studies found any significant mtDNA depletion
associated with this toxicity. If we define PAZT as the probability
of strand termination from a given concentration of AZT
triphosphate and P3TC as the probability from a given 3TC
triphosphate concentration, then the combination of the two drugs
should result in a strand termination probability of
PAZTz3TC~1{ 1{PAZT ðÞ 1{P3TC ðÞ
This equation assumes there is no interaction between the two
nucleoside analog drugs (this is known as the Webb fractional
effect [53]). Note that PAZT+3TC is here defined as one minus the
probability that neither AZT nor 3TC independently cause strand
termination. A set of 1000 simulations was repeated 10 times,
using the medium dNTP concentrations defined in Table 3, and
mean and standard deviations for the probabilities PAZT,P 3TC and
PAZT+3TC were measured. The results for PAZT+3TC were
consistent with the probability expected assuming no interaction
between the two drugs (Figure 4). This indicates that any
synergistic effects of multiple NRTIs on mitochondrial toxicity
are not consequences of direct strand termination. Alternative
explanations for synergistic effects may include competitive
Table 4. IC50 values for light strand termination calculated from the simulation.
Analog
IC50Values (mM)
with High dNTP
IC50 Values (mM) with
Medium dNTP
IC50 Values (mM)
with Low dNTP
Reported mtDNA
Depletion
Citations for mtDNA
Depletion
ddC-TP 3.42610
24 2.38610
24 5.80610
25 Yes [8,11]
ddA-TP 4.42610
24 2.89610
24 7.47610
25 Yes [8,11]
d4T-TP 7.92610
24 4.65610
24 9.76610
25 Yes [8,11]
FTC(+)-TP 5.90610
23 4.20610
23 9.80610
24 No data NA
3TC(+)-TP 3.54610
22 2.26610
22 6.30610
23 No data NA
Acyclovir-TP 6.78610
22 2.58610
22 3.81610
23 No data NA
ddI-TP 0.25 0.17 4.60610
22 No data NA
3TC(2)-TP 0.56 0.40 8.40610
22 No [11,55]
TDF-TP 1.18 0.87 0.22 No [68,69]
AZT2001-TP 3.95 2.38 0.50 No [9,11,18,19,56–62]
FTC(2)-TP 778.9 58.59 7.57 No
ABC-TP NA NA 8.10 No [15]
AZT2007-TP NA NA NA No [9,11,18,19,56–62]
Analogs are listed in order of increasing IC50.I C 50 values are calculated for three different sets of mitochondrial dNTP levels; high, medium and low, as defined in Table 3.
NA, not applicable.
doi:10.1371/journal.pcbi.1000261.t004
Table 5. Reported intracellular concentrations of the
activated (tri-phosphate) form of the nucleoside and
nucleotide analogs, measured in peripheral blood
mononuclear cells in patients.
Activated Analog Intracellular Concentration Range (mM)
3TC-TP 35.4–51.2
FTC(2)-TP 0.40–4.50
AZT-TP 0.84–1.2
ABC-TP 0.04–0.75
TDF-TP 0.27–0.39
ddA-TP 0.013–0.078
d4T-TP 0.016–0.082
Acyclovir-TP Not available
ddC-TP Not available
doi:10.1371/journal.pcbi.1000261.t005
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the limits of this computational model.
Discussion
Our simulated IC50 values of mtDNA strand termination for
AZT-TP, CBV-TP (ABC), FTC(2)-TP and TDF-DP were
approximately 1,000-fold or more higher than those of the di-
deoxy drugs. This agrees with the lack of observed mtDNA
depletion in liver, fat, and PBMC samples from patients on
regimens comprised of NRTIs that are not di-deoxy analogs
[8,9,11]. The herpes drug Acyclovir (ACV) fell between the di-
deoxy drugs and the others in terms of probability of causing
mtDNA strand termination. ACV is not associated with
mitochondrial toxicity clinically. This is believed to be due to
the fact that the drug must be activated by a viral-encoded kinase
[54]. As herpes replication tends to occur in waves with long latent
periods, this may not lead to the long term effects on mitochondria
seen with NRTI use for HIV treatment.
The Di-deoxy Drugs
The di-deoxy NRTIs (ddC, ddA, and d4T) showed the greatest
risk of strand termination in our simulations, indicated by their
predicted low IC50 values. This agrees with previous studies
showing they are the NRTIs most associated with mtDNA
depletion in vitro [14–16,18,19,55] and mitochondria-related
toxicities clinically placing them as alternative drugs in the federal
guidelines [1]. In both muscle and subcutaneous fat biopsies of
HIV+ patients, mtDNA levels were significantly lower in those on
di-deoxy drug regimens as opposed to those on non-di-deoxy
NRTI regimens [8,11]. Even though the toxic side effects of di-
deoxy drugs are well known and the in vitro effects on tissue
mtDNA levels of these drugs are in agreement with our simulation
Figure 3. The relationship between the IC50 values and the specificity constant, kcat/Km. The specificity constant is a measurement of
direct interaction with polymerase-c often used as prediction for analog incorporation. The IC50 values are a more direct measure of incorporation
probability taking exonuclease activity and other features into account. This relationship shows that the specificity constant is a useful proxy for
incorporation probability.
doi:10.1371/journal.pcbi.1000261.g003
Table 6. The effect of the exonuclease reaction for each
nucleoside or nucleotide analog, in order of increasing Vexo.
Analog Vexo (1/s) Pexo 1-Pexo IC50/IC50(exo-)
ddC 0.00002 0.00040 0.9996 1
d4T 0.0004 0.0079 0.9921 0.98
AZT2001 0.0004 0.0079 0.9921 1.038
AZT2007 Not reported - - -
ddA 0.0005 0.01 0.99 1.086
ddI 0.0007 0.014 0.986 1.059
TDF 0.0007 0.014 0.986 0.942
ABC 0.0016 0.031 0.969 -
Acyclovir 0.0021 0.040 0.96 0.919
FTC(2) 0.0048 0.088 0.912 0.964
FTC(+) 0.0048 0.088 0.912 0.867
3TC(2) 0.015 0.23 0.77 0.725
3TC(+) 0.02 0.29 0.71 0.69
doi:10.1371/journal.pcbi.1000261.t006
Figure 4. The computed probability of strand termination for
an AZT and 3TC combination. Computed probabilities are shown
for AZT-TP alone (at 0.5 mM), 3TC-TP alone (at 0.1 mM) and the
combination of both drugs at those concentrations (solid bars). The
error bars represent standard deviations from 10 repeated sets of 1000
simulations. Also shown is the predicted probability of strand
termination for the combined drugs (hatched bar) with the assumption
of no interaction between the two drugs, calculated from the equation
given in the text.
doi:10.1371/journal.pcbi.1000261.g004
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3610
24 mM warrant discussion. The low IC50 value for ddC is in
agreement with findings that this drug is not readily metabolized in
the cell to its active form [16,47], implying that the concentrations
of the activated drug in the cell may be quite small. There is
evidence, however, that d4T and ddI are activated to a significant
degree as the concentration of their triphosphorylated forms in
patient peripheral blood mononuclear cells are above the
predicted IC50 values by approximately 100-fold [43,44]
(Table 5, note that the experimentally measured value is the
activated drug concentration in the cytoplasm, not in the
mitochondria). Given that d4T and ddI are still recommended
drugs for HAART [1] they are obviously tolerable to a large
number of patients who do not experience the serious side-effects
of lactic acidosis and neuropathy. One plausible explanation for
this tolerance in the face of the striking affinity of these drugs for
pol-c is that there exists a significant barrier to di-deoxy drug entry
into the mitochondrion or drug activation within the mitochon-
drion allowing activated di-deoxy drug mitochondrial concentra-
tions to remain low in the majority of patients treated with these
drugs. We know of no reports of measured levels of the
triphosphate form of these di-deoxy drugs within mitochondria.
AZT
The experimental data indicates that AZT interacts poorly with
pol-c as shown by the high Km and low kcat values (Table 2) for
this drug. An explanation for the slow rate of incorporation of
AZT was recently published [27]. AZT demonstrates unusually
slow pyrophosphate release upon incorporation by pol-c rendering
polymerization readily reversible even upon binding to the
template:primer molecule. In the cases of natural nucleotides this
subreaction is fast enough to be considered negligible indicating
that pre-steady state kpol values are a good approximation for kcat.
Yet, in the case of AZT, this slow pyrophosphate release rate has a
significant effect on kcat so that a measurement of kpol during
steady-state conditions is more appropriate for estimating kcat. The
kpol and Kd determined in the recent Hanes and Johnson study
[27] with steady-state conditions, that theoretically take the slow
pyrophosphate release rate in to account, indicate a kcat 100-fold
lower than that determined from the kpol calculated under pre-
steady state conditions [25]. We carried out the simulation for
both sets of parameters separately and in both cases AZT shows a
poor probability of mtDNA strand termination (Figure 2). The
IC50 values generated by this study show that AZT should not be
toxic through mtDNA strand termination as it has a higher IC50
value than 3TC(2) and TDF, neither of which are associated with
mitochondrial toxicity.
The low probability of strand termination by AZT is supported
by the fact that although AZT has consistently been associated
with positive markers for mitochondrial toxicity, substantial
evidence exists that the extent of AZT-induced mitochondrial
toxicity is disproportional to the amount of mtDNA depletion it
causes. The analogs ddC, d4T and ddI (activated to ddA) cause
significantly more mtDNA depletion and decreased protein
subunit expression of various electron transfer chain proteins with
essential subunits encoded in the mtDNA, as would be expected
from their increased interaction with pol-c compared to other
analogs (Figure 2). Yet AZT still manages to demonstrate a
cytotoxicity that is equal to or greater than ddA, ddC, and d4T at
comparable concentrations in various studies. In human liver and
cardiac muscle cells incubation with AZT lead to cytotoxicity and
increased lactate levels with no sign of mtDNA depletion
[18,56,57]. Similar results are seen in blood cells and adipose
cells [19,58,59]. Szabados et al. [60] showed significant toxic
effects on cardiac muscle cells including increased ROS, abnormal
mitochondrial structure, and decreased ATP/ADP ratio after two
weeks of exposure of cells in medium with no effects on mtDNA
levels. In fact, AZT is actually associated with slight increase in
mtDNA levels in cell culture [61,62], PBMCs [9], and liver tissue
samples [11]. Our model, however, does not address subreactions
that influence pol-c binding of the analog, meaning our results
cannot disprove the possibility that AZT toxicity is due to
deactivating pol-c either through irreversible binding or induction
of a conformational change in the enzyme. However, the high Kd
determined by both Hanes and Johnson and Johnson et al.
[25,27], along with the cited studies showing toxicity independent
of mtDNA depletion, make this an improbable mode of toxicity. It
is our conclusion that based on the measured kinetic coefficients of
AZT with pol-c that AZT toxicity is not dependent upon mtDNA
strand termination. Indeed, various pol-c independent hypotheses
have been proposed for AZT mitochondrial toxicity. These
include inhibition of the enzymes of the mitochondrial salvage
pathway causing nucleotide pool imbalances [63], binding to
ADP-ATP translocator [64], and direct inhibition of components
of the electron transport chain [65].
TDF
Tenofovir is associated with renal dysfunction without signifi-
cant mtDNA depletion [66,67]. In a retrospective study of HIV
positive patients taking TDF and those not taking TDF, no
significant differences in mtDNA levels of kidney biopsies were
observed [68]. Similarly, in human renal proximal tubule cells
[69], TDF was not associated with cytotoxicity, mtDNA depletion,
or COII mRNA depletion. In our simulations mitochondrial TDF
triphosphate IC50 values were in the range 0.2 to 1.2 mM,
depending on the natural dNTP levels. Since these concentrations
are not unusually high, our conclusion is that Tenofovir might be
able to cause some moderate mtDNA depletion, depending on
how well the activated drug is concentrated within the mitochon-
drion.
Conclusions
A number of hypothesis with supporting evidence have been
proposed for NRTI toxicity experienced during HAART. Possible
pol-c mediated pathways include the direct inhibition of pol-c by
NRTI-triphosphate without incorporation of the analog; chain
termination by incorporation of NRTI triphosphate into mtDNA;
and incorporation without chain termination of the analog-
triphosphate allowing it to remain as a point mutation in mtDNA.
Our model only addresses the case of chain termination. There is
not enough data on the subreactions that comprise analog binding
to pol-c for this model to explore the possibility that some analogs
cause toxicity through inhibition of the pol-c enzyme directly,
either by irreversible binding or induction of conformational
change, as opposed to strand termination.
The specificity constant, kcat/Km, [25] is commonly used as an
approximate indicator of mitochondrial toxicity through strand
termination of mtDNA. Before this model, this has been a bit of a
leap as the specificity constant does not take genome length,
exonuclease activity, nor dNTP concentration into account, and
no direct predictions or measurements of strand termination
probabilities have previously been given. We fill this gap in our
understanding by providing a model that includes all of these
factors and that predicts strand termination probabilities. The
consistence between our simulation model results and the
qualitative ordered list of NRTI drug toxicity based on the
specificity constant is a validation of the model results. However,
the simulation model goes far beyond the specificity constant by
mtDNA Strand Termination by NRTIs
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(Figure 2) for these drugs. Furthermore, the specific definition of
strand termination used in this model raises the hypothesis that
dissociation of polymerase-c after an NRTI is incorporated into
the mtDNA strand is a critical step in strand termination. In this
particular model we chose to define strand termination as the
dissociation of polymerase-c after the incorporation of an NRTI,
under the assumption that re-association of the polymerase after
the NRTI could not occur. Of course, it is possible that in-vivo
there may be other currently unknown factors which may alter the
polymerase-c dissociation kinetics (or any other kinetics for that
matter) from the measured values. If our assumption that pol-c re-
association is blocked after NRTI incorporation was changed, and
re-association of the polymerase was to be allowed, then more
exonuclease events of the NRTIs would occur. However, it is not
clear to us then what the definition of ‘‘strand termination’’ would
be since the exonuclease activity would eventually remove all
incorporated NRTIs given enough time. Johnson et al [25] used
that assumption, where all NRTIs incorporated into the mtDNA
were eventually removed by exonuclease activity, to define a
toxicity index based on a calculation of the amount of additional
time required for these NRTI exonuclease events. Based on this
definition of a toxicity index, Johnson et al [25] also defined an
ordered list of NRTI drug toxicity which was similar to our list and
similar to the lists based on the specificity constants. An important
use of any computational model is to raise questions for further
experimental study. This simulation raises the following questions.
Is strand termination defined by the dissociation of the polymerase
after insertion of an activated NRTI? If not, what is the proper
definition of strand termination?
NRTI toxicity appears perplexingly specific to cell type [1] and
the mechanism for this tissue specificity is currently unclear. As
natural nucleotide concentrations within the mitochondrion can
differ greatly across cell types, we sought to observe how
incorporation of NRTIs may differ in the presence of varying
mitochondrial dNTP levels, which we broke down into three
sample categories; high dNTP levels, medium dNTP levels and
low dNTP levels (Table 3). Although the IC50 values for strand
termination measured in this simulation did depend on the
concentrations of the natural nucleotide triphosphates, the relative
ordering of the nucleoside analogs by IC50 was the same for all
three dNTP conditions (Table 4). The simulations made with low
dNTP concentrations, representing post-mitotic tissues, did have
lower IC50 values, consistent with a greater sensitivity of these
tissues to damage by nucleoside analog drugs. However, these
results would not explain why some tissues are susceptible to
toxicity from a particular analog. We have limited this simulation
model to the activity of the mitochondrial DNA polymerase acting
on the tri-phosphate form of the four natural deoxyribonucleosides
and the tri-phosphate form of the drugs. Since the tissue
dependence of the toxicity of the drugs was not reproduced in
this model, this implies that the source of this tissue dependence
lies outside the bounds of this particular model. This includes the
possible interference of the various phosphate states of the drugs
with the metabolism within the mitochondria that produces the
natural deoxyribonucleoside tri-phosphates, potentially altering
the relative levels of the four natural dNTPs.
Although mitochondrial toxicity from NRTIs is common, the
more severe forms of this toxicity are certainly not universal.
Current research is revealing that the gene for polymerase-c is the
site of a large number of mutations and polymorphisms that alter
its enzyme kinetics and function [70–73]. The natural variability
in this crucial gene may be an important source of the individual
variation in the susceptibility of patients to this toxicity, and
perhaps to the phenotypic variation which occurs. Although the
interaction of nucleoside analogs with polymerase-c has been
recognized for almost 15 years now [6], we still know surprisingly
little about the levels of activated drugs within mitochondria [63]
or about the transport mechanism by which these drugs enter the
mitochondrion [74,75].
Supporting Information
Text S1 Supplemental tables of model parameter values and
additional results
Found at: doi:10.1371/journal.pcbi.1000261.s001 (0.03 MB PDF)
Author Contributions
Conceived and designed the experiments: YC DCS. Performed the
experiments: KVW ZS. Analyzed the data: KVW ZS. Contributed
reagents/materials/analysis tools: YC. Wrote the paper: KVW ZS DCS.
References
1. Antiretroviral_Guidelines_for_Adults_and_Adolescents_Panel (2006) Guidelines
for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents.
pp 11–20. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.
pdf.
2. Anderson PL, Kakuda TN, Lichtenstein KA (2004) The cellular pharmacology
of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its
relationship to clinical toxicities. Clin Infect Dis 38: 743–753.
3. Ray AS (2005) Intracellular interactions between nucleos(t)ide inhibitors of HIV
reverse transcriptase. AIDS Rev 7: 113–125.
4. d’Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, et al. (2000)
Insights into the reasons for discontinuation of the first highly active
antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive
patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive
Patients. AIDS 14: 499–507.
5. Copeland WC (2008) Inherited mitochondrial diseases of DNA replication.
Annu Rev Med 59: 131–146.
6. Martin JL, Brown CE, Matthews-Davis N, Reardon JE (1994) Effects of antiviral
nucleoside analogs on human DNA-polymerases and mitochondrial-DNA
synthesis. Antimicrob Agents Chemother 38: 2743–2749.
7. Lewis W, Day BJ, Copeland WC (2003) Mitochondrial toxicity of NRTI
antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2:
812–822.
8. Cherry CL, Gahan ME, McArthur JC, Lewin SR, Hoy JF, et al. (2002)
Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in
subcutaneous fat. J Acquir Immune Defic Syndr 30: 271–277.
9. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, et al. (2002)
Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-
infected patients. N Engl J Med 346: 811–820.
10. Haugaard SB, Andersen O, Pedersen SB, Dela F, Richelsen B, et al. (2005)
Depleted skeletal muscle mitochondrial DNA, hyperlactatemia, and decreased
oxidative capacity in HIV-infected patients on highly active antiretroviral
therapy. J Med Virol 77: 29–38.
11. Walker UA, Bauerle J, Laguno M, Murillas J, Mauss S, et al. (2004) Depletion of
mitochondrial DNA in liver under antiretroviral therapy with didanosine,
stavudine, or zalcitabine. Hepatology 39: 311–317.
12. Azzam R, Lal L, Goh SL, Kedzierska K, Jaworowski A, et al. (2006) Adverse
effects of antiretroviral drugs on HIV-1-infected and -uninfected human
monocyte-derived macrophages. J Acquir Immune Defic Syndr 42: 19–28.
13. Benbrik E, Chariot P, Bonavaud S, AmmiSaid M, Frisdal E, et al. (1997)
Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and
zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci 149: 19–25.
14. Biesecker G, Karimi S, Desjardins J, Meyer D, Abbott B, et al. (2003) Evaluation
of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats,
rhesus monkeys and woodchucks. Antiviral Res 58: 217–225.
15. Birkus G, Hitchcock MJM, Cihlar T (2002) Assessment of mitochondrial toxicity
in human cells treated with tenofovir: comparison with other nucleoside reverse
transcriptase inhibitors. Antimicrob Agents Chemother 46: 716–723.
16. Cui LX, Locatelli L, Xie MY, Sommadossi JP (1997) Effect of nucleoside
analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12
cells. J Pharmacol Exp Ther 280: 1228–1234.
mtDNA Strand Termination by NRTIs
PLoS Computational Biology | www.ploscompbiol.org 9 January 2009 | Volume 5 | Issue 1 | e100026117. Galluzzi L, Pinti M, Troiano L, Prada N, Nasi M, et al. (2005) Changes in
mitochondrial RNA production in cells treated with nucleoside analogues.
Antivir Ther 10: 191–195.
18. Pan-Zhou XR, Cui LX, Zhou XJ, Sommadossi JP, Darley-Usmar VM (2000)
Differential effects of antiretroviral nucleoside analogs on mitochondrial function
in HepG2 cells. Antimicrob Agents Chemother 44: 496–503.
19. Setzer B, Schlesier M, Thomas AK, Walker UA (2005) Mitochondrial toxicity of
nucleoside analogues in primary human lymphocytes. Antivir Ther 10: 327–334.
20. Walker UA, Setzer B, Venhoff N (2002) Increased long-term mitochondrial
toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors.
AIDS 16: 2165–2173.
21. Lewis W, Kohler JJ, Hosseini SH, Haase CP, Copeland WC, et al. (2006)
Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA:
evidence supporting the DNA pol gamma hypothesis. AIDS 20: 675–684.
22. Note R, Maisonneuve C, Letteron P, Peytavin G, Djouadi F, et al. (2003)
Mitochondrial and metabolic effects of nucleoside reverse transcriptase
inhibitors (NRTIs) in mice receiving one of five single- and three dual-NRTI
treatments. Antimicrob Agents Chemother 47: 3384–3392.
23. Piechota J, Szczesny R, Wolanin K, Chlebowski A, Bartnik E (2006) Nuclear
and mitochondrial genome responses in HeLa cells treated with inhibitors of
mitochondrial DNA expression. Acta Biochim Pol 53: 485–495.
24. McComsey G, Bai RK, Maa JF, Seekins D, Wong LJ (2005) Extensive
investigations of mitochondrial DNA genome in treated HIV-infected subjects:
beyond mitochondrial DNA depletion. J Acquir Immune Defic Syndr 39:
181–188.
25. Johnson AA, Ray AS, Hanes J, Suo ZC, Colacino JM, et al. (2001) Toxicity of
antiviral nucleoside analogs and the human mitochondrial DNA polymerase.
J Biol Chem 276: 40847–40857.
26. Feng JY, Murakami E, Zorca SM, Johnson AA, Johnson KA, et al. (2004)
Relationship between antiviral activity and host toxicity: comparison of the
incorporation efficiencies of 29,39-dideoxy-5-fluoro-39-thiacytidine-triphosphate
analogs by human immunodeficiency virus type 1 reverse transcriptase and
human mitochondrial DNA polymerase. Antimicrob Agents Chemother 48:
1300–1306.
27. Hanes JW, Johnson KA (2007) A novel mechanism of selectivity against AZT by
the human mitochondrial DNA polymerase. Nucleic Acids Res 35: 6973–6983.
28. Hanes JW, Zhu Y, Parris DS, Johnson KA (2007) Enzymatic therapeutic index
of acyclovir. Viral versus human polymerase gamma specificity. J Biol Chem
282: 25159–25167.
29. Feng JY, Anderson KS (1999) Mechanistic studies comparing the incorporation
of (+)a n d( 2) isomers of 3TCTP by HIV-1 reverse transcriptase. Biochemistry
38: 55–63.
30. Colacino JM (1996) Mechanisms for the anti-hepatitis B virus activity and
mitochondrial toxicity of fialuridine (FIAU). Antivir Res 29: 125–139.
31. Lewis W, Levine ES, Griniuviene B, Tankersley KO, Colacino JM, et al. (1996)
Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of
multiple adjacent analog incorporation, decrease mtDNA abundance, and cause
mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad
Sci U S A 93: 3592–3597.
32. Gillespie D (1976) General method for numerically simulating stochastic time
evolution of coupled chemical-reactions. J Comput Phys 22: 403–434.
33. Gillespie DT (1977) Exact stochastic simulation of coupled chemical reactions.
J Phys Chem 81: 2340–2361.
34. Johnson AA, Johnson KA (2001) Exonuclease proofreading by human
mitochondrial DNA polymerase. J Biol Chem 276: 38097–38107.
35. Johnson AA, Johnson KA (2001) Fidelity of nucleotide incorporation by human
mitochondrial DNA polymerase. J Biol Chem 276: 38090–38096.
36. Lee HR, Johnson KA (2006) Fidelity of the human mitochondrial DNA
polymerase. J Biol Chem 281: 36236–36240.
37. Ferraro P, Pontarin G, Crocco L, Fabris S, Reichard P, et al. (2005)
Mitochondrial deoxynucleotide pools in quiescent fibroblasts - A possible model
for mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). J Biol
Chem 280: 24472–24480.
38. Rampazzo C, Ferraro P, Pontarin G, Fabris S, Reichard P, et al. (2004)
Mitochondrial deoxyribonucleotides, pool sizes, synthesis, and regulation. J Biol
Chem 279: 17019–17026.
39. Pollak JK, Munn EA (1970) The isolation by isopycnic density-gradient
centrifugation of two mitochondrial populations from livers of embryonic and
fed and starved adult rats. Biochem J 117: 913–919.
40. Friis MB, Friborg CR, Schneider L, Nielsen MB, Lambert IH, et al. (2005) Cell
shrinkage as a signal to apoptosis in NIH 3T3 fibroblasts. J Physiol 567:
427–443.
41. Ferraro P, Nicolosi L, Bernardi P, Reichard P, Bianchi V (2006) Mitochondrial
deoxynucleotide pool sizes in mouse liver and evidence for a transport
mechanism for thymidine monophosphate. Proc Natl Acad Sci U S A 103:
18586–18591.
42. Barry MG, Khoo SH, Veal GJ, Hoggard PG, Gibbons SE, et al. (1996) The
effect of zidovudine dose on the formation of intracellular phosphorylated
metabolites. AIDS 10: 1361–1367.
43. Becher F, Landman R, Mboup S, Kane CN, Canestri A, et al. (2004)
Monitoring of didanosine and stavudine intracellular trisphosphorylated
anabolite concentrations in HIV-infected patients. AIDS 18: 181–187.
44. Becher F, Pruvost A, Goujard C, Guerreiro C, Delfraissy JF, et al. (2002)
Improved method for the simultaneous determination of d4T, 3TC and ddl
intracellular phosphorylated anabolites in human peripheral-blood mononuclear
cells using high-performance liquid chromatography/tandem mass spectrome-
try. Rapid Commun Mass Spectrom 16: 555–565.
45. Kewn S, Hoggard PG, Sales SD, Jones K, Maher B, et al. (2002) Development
of enzymatic assays for quantification of intracellular lamivudine and carbovir
triphosphate levels in peripheral blood mononuclear cells from human
immunodeficiency virus-infected patients. Antimicrob Agents Chemother 46:
135–143.
46. Moore KH, Barrett JE, Shaw S, Pakes GE, Churchus R, et al. (1999) The
pharmacokinetics of lamivudine phosphorylation in peripheral blood mononu-
clear cells from patients infected with HIV-1. AIDS 13: 2239–2250.
47. Piliero PJ (2004) Pharmacokinetic properties of nucleoside/nucleotide reverse
transcriptase inhibitors. J Acquir Immune Defic Syndr 37 Suppl 1: S2–S12.
48. Pruvost A, Negredo E, Benech H, Theodoro F, Puig J, et al. (2005)
Measurement of intracellular didanosine and tenofovir phosphorylated metab-
olites and possible interaction of the two drugs in human immunodeficiency
virus-infected patients. Antimicrob Agents Chemother 49: 1907–1914.
49. Longley MJ, Mosbaugh DW (1991) Properties of the 39 to 59 exonuclease
associated with porcine liver DNA polymerase c. Substrate specificity, product
analysis, inhibition, and kinetics of terminal excision. J Biol Chem 266:
24702–24711.
50. Eriksson S, Xu B, Clayton DA (1995) Efficient incorporation of anti-HIV
deoxynucleotides by recombinant yeast mitochondrial DNA polymerase. J Biol
Chem 270: 18929–18934.
51. Chan SSL, Santos JH, Meyer JN, Mandavilli BS, Cook DL, et al. (2007)
Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to
AZT, 3TC, or AZT/3TC in combination. Environ Mol Mutagen 48: 190–200.
52. Venhoff N, Setzer B, Melkaoui K, Walker UA (2007) Mitochondrial toxicity of
tenofovir, emtricitabine and abacavir alone and in combination with additional
nucleoside reverse transcriptase inhibitors. Antivir Ther 12: 1075–1085.
53. Martinez-Irujo JJ, Villahermosa ML, Mercapide J, Cabodevilla JF, Santiago E
(1998) Analysis of the combined effect of two linear inhibitors on a single
enzyme. Biochem J 329: 689–698.
54. Coen DM, Schaffer PA (1980) Two distinct loci confer resistance to
acycloguanosine in herpes simplex virus type 1. Proc Natl Acad Sci U S A
77: 2265–2269.
55. Cote HCF, Yip B, Asselin JJ, Chan JW, Hogg RS, et al. (2003) Mitochondrial:
nuclear DNA ratios in peripheral blood cells from human immunodeficiency
virus (HIV)-infected patients who received selected HIV antiretroviral drug
regimens. J Infect Dis 187: 1972–1976.
56. Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJM (2002) Tenofovir exhibits
low cytotoxicity in various human cell types: comparison with other nucleoside
reverse transcriptase inhibitors. Antiviral Res 54: 37–45.
57. Lund KC, Peterson LL, Wallace KB (2007) Absence of a universal mechanism
of mitochondrial toxicity by nucleoside analogs. Antimicrob Agents Chemother
51: 2531–2539.
58. Mallon PW, Unemori P, Sedwell R, Morey A, Rafferty M, et al. (2005) In vivo,
nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial
and lipid metabolism genes in the absence of depletion of mitochondrial DNA.
J Infect Dis 191: 1686–1696.
59. Stankov MV, Lucke T, Das AM, Schmidt RE, Behrens GMN (2007)
Relationship of mitochondrial DNA depletion and respiratory chain activity in
preadipocytes treated with nucleoside reverse transcriptase inhibitors. Antivir
Ther 12: 205–216.
60. Szabados E, Fischer GM, Toth K, Csete B, Nemeti B, et al. (1999) Role of
reactive oxygen species and poly-ADP-ribose polymerase in the development of
AZT-induced cardiomyopathy in rat. Free Radic Biol Med 26: 309–317.
61. de Baar MP, de Rooij ER, Smolders KG, van Schijndel HB, Timmermans EC,
et al. (2007) Effects of apricitabine and other nucleoside reverse transcriptase
inhibitors on replication of mitochondrial DNA in HepG2 cells. Antiviral Res
76: 68–74.
62. Hobbs GA, Keilbaugh SA, Rief PM, Simpson MV (1995) Cellular targets of 39-
azido-39-deoxythymidine: an early (non-delayed) effect on oxidative phosphor-
ylation. Biochem Pharmacol 50: 381–390.
63. Lynx MD, Bentley AT, McKee EE (2006) 39-Azido-39-deoxythymidine (AZT)
inhibits thymidine phosphorylation in isolated rat liver mitochondria: a possible
mechanism of AZT hepatotoxicity. Biochem Pharmacol 71: 1342–1348.
64. Valenti D, Barile M, Passarella S (2000) AZT inhibition of the ADP/ATP
antiport in isolated rat heart mitochondria. Int J Mol Med 6: 93–96.
65. Pereira LF, Oliveira MB, Carnieri EG (1998) Mitochondrial sensitivity to AZT.
Cell Biochem Funct 16: 173–181.
66. Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, et al. (2003) Tenofovir-
related nephrotoxicity in human immunodeficiency virus-infected patients: three
cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus.
Clin Infect Dis 36: 1070–1073.
67. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, et al. (2006)
Tenofovir-associated acute and chronic kidney disease: a case of multiple drug
interactions. Clin Infect Dis 42: 283–290.
68. Cote HC, Magil AB, Harris M, Scarth BJ, Gadawski I, et al. (2006) Exploring
mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction
among HIV-infected patients on highly active antiretroviral therapy. Antivir
Ther 11: 79–86.
69. Vidal F, Domingo JC, Guallar J, Saumoy M, Cordobilla B, et al. (2006) In vitro
cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination
mtDNA Strand Termination by NRTIs
PLoS Computational Biology | www.ploscompbiol.org 10 January 2009 | Volume 5 | Issue 1 | e1000261with other antiretrovirals in human renal proximal tubule cells. Antimicrob
Agents Chemother 50: 3824–3832.
70. Graziewicz MA, Bienstock RJ, Copeland WC (2007) The DNA polymerase c
Y955C disease variant associated with PEO and parkinsonism mediates the
incorporation and translesion synthesis opposite 7,8-dihydro-8-oxo-29-deoxy-
guanosine. Human Mol Genet 16: 2729–2739.
71. Hudson G, Chinnery PF (2006) Mitochondrial DNA polymerase-c and human
disease. Hum Mol Genet 15: R244–R252.
72. Horvath R, Hudson G, Ferrari G, Futterer N, Ahola S, et al. (2006) Phenotypic
spectrum associated with mutations of the mitochondrial polymerase gamma
gene. Brain 129: 1674–1684.
73. Graziewicz MA, Longley MJ, Copeland WC (2006) DNA polymerase gamma in
mitochondrial DNA replication and repair. Chem Rev 106: 383–405.
74. Kang J, Samuels DC (2008) The evidence that the DNC (SLC25A19) is not the
mitochondrial deoxyribonucleotide carrier. Mitochondrion 8: 103–108.
75. Lindhurst MJ, Fiermonte G, Song SW, Struys E, De Leonardis F, et al. (2006)
Knockout of Slc25a19 causes mitochondrial thiamine pyrophosphate depletion,
embryonic lethality, CNS malformations, and anemia. Proc Natl Acad Sci U S A
103: 15927–15932.
mtDNA Strand Termination by NRTIs
PLoS Computational Biology | www.ploscompbiol.org 11 January 2009 | Volume 5 | Issue 1 | e1000261